Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center.
Pizzoferrato M, de Sire R, Ingravalle F, Mentella MC, Petito V, Martone AM, Landi F, Miggiano GAD, Mele MC, Lopetuso LR, Schiavoni E, Napolitano D, Turchini L, Poscia A, Nicolotti N, Papa A, Armuzzi A, Scaldaferri F, Gasbarrini A. Pizzoferrato M, et al. Among authors: napolitano d. Nutrients. 2019 Sep 24;11(10):2281. doi: 10.3390/nu11102281. Nutrients. 2019. PMID: 31554166 Free PMC article.
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre.
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Scaldaferri F, et al. Among authors: napolitano d. United European Gastroenterol J. 2020 Aug;8(7):775-781. doi: 10.1177/2050640620929133. Epub 2020 May 21. United European Gastroenterol J. 2020. PMID: 32438878 Free PMC article.
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period.
Scaldaferri F, Papa A, Napolitano D, Rizzatti G, Pistone MT, Poscia A, Volpe M, Lopetuso LR, Schiavoni E, Guidi L, Gaetani E, Holleran G, Cammarota G, Rapaccini G, Pugliese D, Ojetti V, Franceschi F, Armuzzi A, Gasbarrini A. Scaldaferri F, et al. Among authors: napolitano d. Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5826-5835. doi: 10.26355/eurrev_202109_26801. Eur Rev Med Pharmacol Sci. 2021. PMID: 34604974 Free article.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Tursi A, et al. Among authors: napolitano d. Expert Opin Biol Ther. 2022 Feb;22(2):313-320. doi: 10.1080/14712598.2022.2007881. Epub 2021 Dec 27. Expert Opin Biol Ther. 2022. PMID: 34904510
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.
Papa A, Scaldaferri F, Covino M, Tursi A, Furfaro F, Mocci G, Lopetuso LR, Maconi G, Bibbò S, Fiorani M, Laterza L, Mignini I, Napolitano D, Parisio L, Pizzoferrato M, Privitera G, Pugliese D, Schepis T, Schiavoni E, Settanni CR, Vetrone LM, Armuzzi A, Danese S, Gasbarrini A. Papa A, et al. Among authors: napolitano d. Biomedicines. 2022 Apr 3;10(4):843. doi: 10.3390/biomedicines10040843. Biomedicines. 2022. PMID: 35453593 Free PMC article.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A. Tursi A, et al. Among authors: napolitano d. Inflamm Bowel Dis. 2023 Mar 1;29(3):376-383. doi: 10.1093/ibd/izac092. Inflamm Bowel Dis. 2023. PMID: 35579320
71 results